Affiliations 

  • 1 Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, United States
  • 2 Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, United States; Department of Pediatrics, University of Texas Medical Branch, Galveston, TX, United States; WHO Collaborating Center, University of Texas Medical Branch, Galveston, TX, United States. Electronic address: gnmillig@utmb.edu
Vaccine, 2016 06 03;34(26):2971-2975.
PMID: 26973068 DOI: 10.1016/j.vaccine.2015.12.075

Abstract

Nipah virus (NiV) is a highly pathogenic, recently emerged paramyxovirus that has been responsible for sporadic outbreaks of respiratory and encephalitic disease in Southeast Asia. High case fatality rates have also been associated with recent outbreaks in Malaysia and Bangladesh. Although over two billion people currently live in regions in which NiV is endemic or in which the Pteropus fruit bat reservoir is commonly found, there is no approved vaccine to protect against NiV disease. This report examines the feasibility and current efforts to develop a NiV vaccine including potential hurdles for technical and regulatory assessment of candidate vaccines and the likelihood for financing.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.